We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) closed at $543.28 in the latest trading session, marking a +1.37% move from the prior day. This move outpaced the S&P 500's daily loss of 0.88%. At the same time, the Dow lost 0.82%, and the tech-heavy Nasdaq gained 0.08%.
Heading into today, shares of the maker of scientific instrument and laboratory supplies had lost 3.65% over the past month, outpacing the Medical sector's loss of 4.6% and the S&P 500's loss of 8.06% in that time.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. On that day, Thermo Fisher Scientific is projected to report earnings of $4.93 per share, which would represent a year-over-year decline of 11.96%. Meanwhile, our latest consensus estimate is calling for revenue of $9.86 billion, up 6.37% from the prior-year quarter.
TMO's full-year Zacks Consensus Estimates are calling for earnings of $22.70 per share and revenue of $42.49 billion. These results would represent year-over-year changes of -9.67% and +8.35%, respectively.
Any recent changes to analyst estimates for Thermo Fisher Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Thermo Fisher Scientific is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Thermo Fisher Scientific's current valuation metrics, including its Forward P/E ratio of 23.6. This valuation marks a discount compared to its industry's average Forward P/E of 27.04.
Investors should also note that TMO has a PEG ratio of 1.82 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 1.91 at yesterday's closing price.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 161, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
Thermo Fisher Scientific (TMO - Free Report) closed at $543.28 in the latest trading session, marking a +1.37% move from the prior day. This move outpaced the S&P 500's daily loss of 0.88%. At the same time, the Dow lost 0.82%, and the tech-heavy Nasdaq gained 0.08%.
Heading into today, shares of the maker of scientific instrument and laboratory supplies had lost 3.65% over the past month, outpacing the Medical sector's loss of 4.6% and the S&P 500's loss of 8.06% in that time.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. On that day, Thermo Fisher Scientific is projected to report earnings of $4.93 per share, which would represent a year-over-year decline of 11.96%. Meanwhile, our latest consensus estimate is calling for revenue of $9.86 billion, up 6.37% from the prior-year quarter.
TMO's full-year Zacks Consensus Estimates are calling for earnings of $22.70 per share and revenue of $42.49 billion. These results would represent year-over-year changes of -9.67% and +8.35%, respectively.
Any recent changes to analyst estimates for Thermo Fisher Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Thermo Fisher Scientific is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Thermo Fisher Scientific's current valuation metrics, including its Forward P/E ratio of 23.6. This valuation marks a discount compared to its industry's average Forward P/E of 27.04.
Investors should also note that TMO has a PEG ratio of 1.82 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 1.91 at yesterday's closing price.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 161, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.